Imagine no Drug War: We could cure depression, addiction, and much more…

JB
March 12th, 2012
alabamatruth.com

(alabamatruth.com) Imagine for a moment that there was no “War on Drugs.” Imagine that we were actually allowed research ancient medicines that have been labeled to have “…no currently accepted medical use in treatment in the United States.” The possibilities to advance medicine and progress human health are endless, unfortunately we are only imagining.

Back in reality the only substances that are allowed to be called and sold as “medicine” are those chemicals that can be patented by the Big Pharma companies. Of course the pills pushed by Big Pharma not only cost you your life savings they also only treat symptoms and usually cause horrible unwanted side effects. But don’t you worry, Big Pharma also owns the patent to the pill that treats that side effect. Anyone else see the circle here?

By large most natural medicines, cures, and treatments actually aim to take care of the cause of the suffering. The medicines mother nature give us are also usually safer and have less unwanted side effects. Now does that mean that everything that grows from the ground is non-toxic and safe to use any way that you want? Absolutely not! The old adage of the poison’s in the dose does apply here. There are many dangerous substances in our natural environment. However, with proper research and education, we will quickly learn that everything on earth has its place and use.

The biggest crime, however, is not the racket run by Big Pharma’s synthetics, it is the suppression of real breakthroughs in treatment of serious conditions by government entities.

Depression, addiction, chronic pain, chronic fatigue, cancer, are all just the beginning of things that could all just be bad memories of years past. If only the substances that are now being found to cure and treat these aliments weren’t banned for any use by none other than the federal government.

Here are just a few examples of what we could be doing to advance modern medicine, if it were only easier to get funding, research, and approval for these treatments:

From NORML.org:

“As clinical research into the therapeutic value of cannabinoids has proliferated – there are now an estimated 20,000 published papers in the scientific literature analyzing marijuana and its constituents — so too has investigators’ understanding of cannabis’ remarkable capability to combat disease. Whereas researchers in the 1970s, 80s, and 90s primarily assessed cannabis’ ability to temporarily alleviate various disease symptoms — such as the nausea associated with cancer chemotherapy — scientists today are exploring the potential role of cannabinoids to modify disease.
Of particular interest, scientists are investigating cannabinoids’ capacity to moderate autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease, as well as their role in the treatment of neurological disorders such as Alzheimer’s disease and amyotrophic lateral sclerosis (a.k.a. Lou Gehrig’s disease.) In fact, in 2009, the American Medical Association (AMA) resolved for the first time in the organization’s history “that marijuana’s status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines.”
Investigators are also studying the anti-cancer activities of cannabis, as a growing body of preclinical and clinical data concludes that cannabinoids can reduce the spread of specific cancer cells via apoptosis (programmed cell death) and by the inhibition of angiogenesis (the formation of new blood vessels). Arguably, these latter findings represent far broader and more significant applications for cannabinoid therapeutics than researchers could have imagined some thirty or even twenty years ago.”

From USAToday.com:

“Psychedelic mushrooms may point to new ways to treat depression, suggest two small brain imaging studies that seem to show how psilocybin — the active ingredient in such mushrooms — affects the brain.One study included 30 healthy people who had psilocybin inserted into their blood while magnetic resonance imaging (MRI) scanners measured changes in their brain activity. The scans revealed that psilocybin caused decreased activity in what the researchers described as the brain’s “hub” regions — areas especially well-connected with other areas.That study was published in this week’s issue of the Proceedings of the National Academy of Sciences.The second study included 10 healthy volunteers and found that psilocybin boosted their recall of personal memories and their emotional well-being for up to two weeks. The researchers said this suggests that psilocybin might prove useful as an adjunct to psychotherapy. That study will be published online Thursday in the British Journal of Psychiatry.

 

From The DailyMail:

Krebs and Johansen set out to independently extract data from previous randomized, controlled clinical trials, pooling their results. They identified six eligible trials, all carried out in the late 1960s and early 1970s. These included 536 participants, the vast majority of whom were male in-patients enrolled in alcohol-focused treatment programs. Individuals with a history of schizophrenia or psychosis were excluded from the original trials. The control conditions included low-dose LSD, stimulants, or non-drug control conditions.While the experiments varied in the dosage used and the type of placebo physicians administered to patients, LSD had a beneficial effect on alcohol misuse in every trial. On average, 59 per cent of LSD patients and 38 per cent of control patients were improved at follow-up using standardized assessment of problem alcohol use.

There was also a similar beneficial effect on maintained abstinence from alcohol. The positive effects of a single LSD dose – reported both in these and in other, non-randomized trials – lasts at least six months and appears to fade by 12 months.

Regarding the lasting effects of the LSD experience in alcoholics, investigators of one trial noted: ‘It was rather common for patients to claim significant insights into their problems, to feel that they had been given a new lease on life, and to make a strong resolution to discontinue their drinking.’

And investigators of another trial noted: ‘It was not unusual for patients following their LSD experience to become much more self-accepting, to show greater openness and accessibility, and to adopt a more positive, optimistic view of their capacities to face future problems.’

‘Given the evidence for a beneficial effect of LSD on alcoholism, it is puzzling why this treatment approach has been largely overlooked,’ says Johansen.”

From asylum.com:

“It’s a plant that might just be the cure to substance abuse, and even though there are entire clinics built around it in Canada, here in the U.S. it remains both illegal and ignored.Ibogaine is an alkaloid derived from the ibogaplant, a perennial rainforest shrub and hallucinogen native to western-central Africa. According to some former slaves to heroin, methamphetamine, cocaine, alcohol and even nicotine, it also breaks the virtually endless cycle of addiction.Canada isn’t the only place where ibogaine is unregulated and available. Clinics there, as well as in Mexico, parts of Europe and dozens of other countries offer a supervised medical setting for the use of ibogaine in addiction withdrawal.

But in America, if you’re looking to try ibogaine as a potential addiction interrupter, you could wind up in even more trouble than when you started.

Under U.S. drug laws, ibogaine is listed as a Schedule 1 substance — meaning it’s considered to have high potential for abuse and no medicinal value — right alongside well-known villains like heroin, LSD and everyone’s favorite bad cousin, cannabis.”

 

Just imagine, if these are just a few examples of the truths that we can find now, think of the possibilities if we were to reform our drug laws. We could be looking at living in a country with empty hospitals and empty prisons…

Leave a Reply

Your email address will not be published. Required fields are marked *